Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Small Cell Lung CancerPlatinum-Sensitive Lung Small Cell CarcinomaExtensive-stage Small-cell Lung Cancer
Interventions
DRUG

Association of lurbinectedin and durvalumab

"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."

DRUG

Association of carboplatin and etoposide

"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"

Trial Locations (1)

33076

Institut Bergonié, Bordeaux

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

PharmaMar

INDUSTRY

lead

Institut Bergonié

OTHER